WPI 2356 Pill - white capsule/oblong, 14mm
Pill with imprint WPI 2356 is White, Capsule/Oblong and has been identified as Topiramate Extended-Release 25 mg. It is supplied by Teva Pharmaceuticals USA, Inc.
Topiramate is used in the treatment of Migraine Prevention; Lennox-Gastaut Syndrome; Seizure Prevention; Epilepsy; Seizures and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 25 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 2356
Topiramate Extended-Release
- Imprint
- WPI 2356
- Strength
- 25 mg
- Color
- White
- Size
- 14.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Carbonic anhydrase inhibitor anticonvulsants
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Teva Pharmaceuticals USA, Inc.
- National Drug Code (NDC)
- 00480-2356
More about topiramate
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,324)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: carbonic anhydrase inhibitor anticonvulsants
- Breastfeeding
Patient resources
- Topiramate drug information
- Topiramate (Advanced Reading)
- Topiramate Tablets
- Topiramate Extended-Release Sprinkle Capsules
- Topiramate Sprinkle Capsules
- Topiramate Extended-Release Capsules
Other brands
Topamax, Trokendi XR, Eprontia, Topamax Sprinkle, ... +2 more
Professional resources
- Topiramate monograph
- Topiramate (FDA)
- Topiramate Capsules (FDA)
- Topiramate ER Capsules (FDA)
- Topiramate Tablets (FDA)
Other brands
Topamax, Trokendi XR, Eprontia, Qudexy XR
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
